Subp. 3.
Asthma and
pulmonary conditions with an asthmatic component.
Asthma and pulmonary conditions with an asthmatic component
may be rated only under this subpart. Ratings under subpart
2 may not be substituted for
or combined with ratings under this subpart.
A. Ratings under this subpart are based on:
(1) the level of bronchial obstruction as
measured by pulmonary function tests done when the individual is on an optimum
treatment regimen but without the addition of inhaled bronchodilator
immediately preceding the pulmonary function testings;
(2) the level of bronchial responsiveness as
measured by standardized methacholine challenge testing;
(3) the need for bronchodilator therapy.
Each element in subitems (1) to (3) must be present for the
rating under that subitem to be assigned.
B. The permanent partial disability for
asthma and pulmonary conditions with an asthmatic component is:
(1) class I: FEV1 and FEV1/FVC are equal to
or greater than 80 percent of predicted, PD20 is greater than 25 milligrams per
milliliter, and no need for persistent bronchodilator therapy, zero
percent;
(2) class II: FEV1 and
FEV1/FVC are equal to or greater than 80 percent of predicted, PD20 is five to
25 milligrams per milliliter, and no need for persistent bronchodilator
therapy, five percent;
(3) class
III: FEV1 and FEV1/FVC are equal to or greater than 80 percent of predicted,
PD20 is five to 25 milligrams per milliliter, and persistent bronchodilator
therapy is required, ten percent;
(4) class IV: FEV1 and FEV1/FVC are equal to
or greater than 80 percent of predicted, PD20 is .025 to four milligrams per
milliliter, and no persistent bronchodilator therapy is required, ten
percent;
(5) class V: FEV1 and
FEV1/FVC are equal to or greater than 80 percent of predicted, PD20 is .025 to
four milligrams per milliliter, and persistent bronchodilator therapy is
required, 13 percent;
(6) class VI:
FEV1 and FEV1/FVC are equal to or greater than 80 percent of predicted, and
PD20 is less than 0.25 milligrams per milliliter, 15 percent;
(7) class VII: FEV1 or FEV1/FVC is less than
80 percent but greater than or equal to 70 percent of predicted, and PD20 is
greater than five milligrams per milliliter, 18 percent;
(8) class VIII: FEV1 or FEV1/FVC is less than
80 percent but greater than or equal to 70 percent of predicted, and PD20 is
0.25 to four milligrams per milliliter, 20 percent;
(9) class IX: FEV1 or FEV1/FVC is less than
80 percent but greater than or equal to 70 percent of predicted, and PD20 is
less than 0.25 milligrams per milliliter, 25 percent;
(10) class X: FEV1 or FEV1/FVC is less than
70 percent but greater than or equal to 60 percent of predicted, and PD20 is
greater than 0.25 milligrams per milliliter, 28 percent;
(11) class XI: FEV1 or FEV1/FVC is less than
70 percent but greater than or equal to 60 percent of predicted, and PD20 is
less than 0.25 milligrams per milliliter, 33 percent;
(12) class XII: FEV1 or FEV1/FVC is less than
60 percent but greater than or equal to 40 percent of predicted, and PD20 is
greater than 0.25 milligrams per milliliter, 50 percent;
(13) class XIII: FEV1 or FEV1/FVC is less
than 60 percent but greater than or equal to 40 percent of predicted, and PD20
is less than 0.25 milligrams per milliliter, 60 percent;
(14) class XIV: FEV1 or FEV1/FVC is less than
40 percent but greater than or equal to 30 percent of predicted, 75
percent;
(15) class XV: FEV1 or
FEV1/FVC is less than 30 percent of predicted, 95 percent.
C. Additional impairment occurs if persistent
steroid therapy is required for the treatment of the asthma or asthmatic
component:
(1) only inhaled steroids
required, add three percent to the otherwise appropriate class in item B, but
the total impairment cannot exceed 95 percent;
(2) if oral steroids are required or oral
steroids and inhaled steroids, add ten percent to the otherwise appropriate
class in item B, but the total impairment cannot exceed 95 percent.